Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib + Gemcitabine in Elderly Advanced NSCLC
NCT00753714Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2008
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Vandetanib + Gemcitabine with Placebo + Gemcitabine (2 arms). Primary endpoint: Progression-Free Survival. Started Oct 2008; status: completed.
02
Drugs
vandetanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00753714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00753714.